Research programme: ubiquitin-modifying therapeutics - Boehringer Ingelheim/Mount Sinai Hospital/University Health Network/University of Toronto

Drug Profile

Research programme: ubiquitin-modifying therapeutics - Boehringer Ingelheim/Mount Sinai Hospital/University Health Network/University of Toronto

Alternative Names: Ubiquitin-binding variants - Boehringer Ingelheim

Latest Information Update: 06 Aug 2014

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Mount Sinai Hospital (Toronto); University Health Network; University of Toronto
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; CNS disorders; Diabetes mellitus; Inflammation

Most Recent Events

  • 22 Jul 2014 Early research in Cancer in Canada (unspecified route)
  • 22 Jul 2014 Boehringer Ingelheim forms a research alliance with the University of Toronto, University Health Network and Mount Sinai Hospital
  • 22 Jul 2014 Early research in Inflammation in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top